pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

2,995 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1776Endpoints1386Fierce Biotech704BioSpace695BioPharma Dive524raps234onclive165fda recalls112fda medwatch
therapy area
allOncology12299Rare Disease3204Immunology2860Cardiology2726Hematology2177Pulmonology2138Vaccines1794
  • AI system Claude decodes a whole genome in 30 minutes, sparking call for result standards
    The author, a Stanford physician‑scientist, used the AI model Claude to analyze his entire genome in roughly half an hour, at a cost of about five dollars. The rapid analysis produced a detailed re…
    STAT · 1mo agoNeutral↗ source
  • Senate finance and health committees brace for major Republican turnover ahead of midterms
    The upcoming midterm elections are set to trigger substantial changes to two Senate committees that oversee health‑care policy. The Senate Finance Committee could see at least five of its 14 Repub…
    STAT · 1mo agoNeutral↗ source
← prev
page 31 of 120
next →
111
globenewswire health73
fda press59
Psychiatry & CNS1204
Ophthalmology1050
Endocrinology & Metabolism775
Pain775
Nephrology759
Former GOP leader Eric Cantor appointed to steer PhRMA amid bipartisan concerns over drug costs
Eric Cantor, former House Republican leader, has been tapped to lead the Pharmaceutical Research and Manufacturers of America (PhRMA) in its Washington lobbying efforts. Cantor previously tried to…
STAT · 1mo agoNeutral↗ source
  • Merck’s antibody impresses with ‘highly competitive’ data in chronic skin disease
    Merck has revealed detailed data for tulisokibart from a mid-stage trial in hidradenitis suppurativa that analysts say could help carve out a place in a crowded market that already includes AbbVie’…
    BioSpace · 1mo agoRegulatoryNeutral↗ source
  • Reporter visits Shanghai to see China’s fast‑growing biotech sector as Chinese‑designed drugs make up about half of the global pipeline
    A STAT+ correspondent traveled to Shanghai to get a first‑hand view of the rapid expansion of China’s biotech industry. The piece describes the bustling research environment and the growing number…
    STAT · 1mo agoNeutral↗ source
  • Blue Shield of California plans to adopt Medicare-inspired chronic-care payment model by 2027
    Blue Shield of California, which serves about 6 million members, is among 17 major health plans that have pledged to adopt payment models based on the Medicare Innovation Center's ACCESS Model. Th…
    STAT · 1mo agoNeutral↗ source
  • Upcoming FDA decisions in Q3 2026 could signal agency flexibility
    The piece highlights five FDA actions slated for the third quarter of 2026 that industry participants are tracking. Observers say the outcomes may reveal how flexible the agency will be under its…
    BioPharma Dive · 1mo agoRegulatoryNeutral↗ source
  • Podcast examines growing US mistrust in science and a new gene-editing lawsuit
    The latest episode of The Readout LOUD, a weekly biotech podcast, focused on the erosion of public confidence in science. Hosts Adam Feuerstein, Elaine Chen, and Allison DeAngelis spoke with STAT’…
    STAT · 1mo agoNeutral↗ source
  • CDC plans to drop disability questions from health survey, sparking concerns of undercounting
    The Centers for Disease Control and Prevention is proposing a redesign of the National Health Interview Survey that would eliminate questions about disabilities. The change is part of a broader eff…
    STAT · 1mo agoRegulatoryNegative↗ source
  • Biopharma job seekers urged to act quickly in Q4 hiring surge
    Biopharma professionals face a busy fourth‑quarter hiring season, and experts say candidates should submit applications as soon as possible rather than waiting. Angie Allen, managing partner at Ka…
    BioSpace · 1mo agoPositive↗ source
  • Trump administration appeals court decision that blocks limits on international student and postdoc visas
    The Department of Homeland Security has filed an appeal after a federal judge ruled that the agency cannot impose new restrictions on how long international students and postdoctoral researchers ma…
    STAT · 1mo agoRegulatoryNeutral↗ source
  • STAT+: MAHA goes corporate
    Health care companies dominate the MAHA Summit, and a look at Trump's watered down effort to lower Medicare drug prices.
    STAT · 1mo ago↗ source
  • Sanofi pays Regeneron $1B upfront to continue search for Dupixent successor
    Sanofi and Regeneron have had a long and “sometimes contentious” partnership, BMO Capital Markets noted, as the companies contend with the looming loss of exclusivity of their blockbuster drug Dupi…
    BioSpace · 1mo ago↗ source
  • Lilly’s EloraTZP combo shows superior weight loss and glucose control, moves to Phase 3
    Eli Lilly reported that its experimental combination, EloraTZP, which pairs an amylin agonist with the approved obesity drug Zepbound, met all primary and secondary goals in a mid‑stage study of ad…
    BioSpace · 1mo agoPositive readoutPositive↗ source
  • Eli Lilly’s Zepbound plus amylin candidate shows 23% weight loss in phase 2 trial, but many patients stopped treatment
    Eli Lilly tested a combination of its GLP‑1 obesity drug Zepbound with the amylin‑targeting candidate eloralintide in a mid‑stage study of people with obesity and type 2 diabetes. After 48 weeks,…
    STAT · 1mo agoPositive readoutNeutral↗ source
  • UnitedHealth lawsuit proceeds as judge rejects motion to dismiss earnings manipulation claims
    A federal judge allowed an investor lawsuit against UnitedHealth Group to continue, rejecting the company's request to throw out the case. The suit alleges UnitedHealth inflated its 2024 earnings…
    STAT · 1mo agoRegulatoryNegative↗ source
  • Trump administration's final Medicare pricing rule limits savings, covering only four firms
    The Trump administration released a final rule intended to lower Medicare prices for drugs administered in physician offices. The rule is part of the Global Benchmark for Efficient Drug Pricing (GL…
    STAT · 1mo agoRegulatoryNegative↗ source
  • HHS launches SURPASS program to accelerate clinical trials using AI and adaptive designs
    HHS announced a new five-year initiative called SURPASS, aimed at speeding up and expanding clinical trials by leveraging artificial intelligence and computational modeling. The program, run throu…
    STAT · 1mo agoRegulatoryPositive↗ source
  • Bristol Myers revises Phase 3 fibrosis trial after liver safety events, including a death
    Bristol Myers Squibb announced a change to its late-stage Phase 3 "Aloft" trial of the experimental pulmonary fibrosis drug admilparant. The amendment adds closer monitoring for liver-related adve…
    BioPharma Dive · 1mo agoNegative readoutNegative↗ source
  • FDA begins review of Roche’s experimental multiple sclerosis pill fenebrutinib
    The FDA has accepted Roche's application for fenebrutinib, an experimental oral therapy for multiple sclerosis, and has started a priority review. The review will evaluate the drug in both relapsi…
    BioPharma Dive · 1mo agoRegulatoryNeutral↗ source
  • U.S. plan to cut Medicaid for legal immigrants, including refugees and trafficking victims, takes effect Oct. 1
    Hundreds of thousands of lawfully present immigrants could lose Medicaid coverage beginning Oct. 1, according to state data. The change is part of the One Big Beautiful Bill Act, a Republican effor…
    STAT · 1mo agoRegulatoryNegative↗ source
  • Atara and Pierre Fabre resubmit Ebvallo cell therapy after second FDA rejection
    Atara Biotherapeutics and Pierre Fabre Pharmaceuticals have filed a new FDA submission for their cell therapy candidate Ebvallo (tabelecleucel), aimed at treating Epstein‑Barr virus‑positive post‑t…
    BioSpace · 1mo agoRegulatoryNeutral↗ source
  • PhRMA appoints former congressman Eric Cantor as CEO as Pierre Fabre resubmits Ebvallo approval request
    PhRMA announced that former U.S. House member Eric Cantor will become its president and chief executive on Nov 9, taking over from longtime leader Steve Ubl. Cantor served Virginia from 2000 to 201…
    BioPharma Dive · 1mo agoRegulatoryNeutral↗ source
  • Poll finds most rural MAHA supporters say Trump health policies have not improved community health
    A new Associated Press‑KFF poll of more than 2,000 rural registered voters shows that while about half of respondents identify with the Make America Healthy Again (MAHA) movement, roughly eight in…
    STAT · 1mo agoNegative↗ source
  • Beam sues over alleged IP theft as Moderna appoints new COO and Pierre Fabre/Atara refile drug for ultra-rare blood cancer
    Beam Therapeutics has filed a lawsuit claiming a former scientist took proprietary information and used it to start a Chinese firm, alleging theft of its intellectual property. PhRMA announced a n…
    STAT · 1mo agoRegulatoryNeutral↗ source